ROCHE HLDGS AG SPN ADR EACH REP 0.125GENUS (RHHBY)

32.14
0.11 0.34
OTC
Prev Close 32.03
Open 31.92
Day Low/High 31.92 / 32.17
52 Wk Low/High 25.25 / 33.77
Volume 820.07K
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 177.38B
Div & Yield N.A. (N.A)

Latest News

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

FDA Approves Genentech's OCREVUS™ (Ocrelizumab) For Relapsing And Primary Progressive Forms Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment

Merck KGaA shares tested one-year highs Friday after the Food & Drug Administration approved rare form of skin cancer treatment that could cost patients as much as $13,000 per month.

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

FDA Grants Breakthrough Therapy Designation For Rituxan® (Rituximab) In Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears

Neurotrope Shares Soar as Alzheimer's Drug Trial Lottery Ticket Call Nears

Despite all the prior failures and blowups, an Alzheimer's drug study -- no matter how unlikely to succeed -- remains an irresistible lure for some investors.

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Poplar Healthcare As Roche Molecular Center Of Excellence

Strategic alliance network is designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized healthcare

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Here's Why Weight Watchers' New CEO Should Be a Woman

Here's Why Weight Watchers' New CEO Should Be a Woman

Could Oprah Winfrey herself take the helm at the diet company?

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

What You Need to Know About Roche AG's Breast Cancer Drug Perjeta

Roche said patients treated with Perjeta combined with Herceptin and chemotherapy after surgery saw lower death risks and tumor return rates.

Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win

Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win

Roche shares surged in Zurich Thursday after the Swiss drugmaker said trials of its key breast cancer drug showed solid results when compared to chemotherapy.

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Phase III APHINITY Study Shows Genentech's Perjeta® Regimen Helped People With An Aggressive Type Of Early Breast Cancer Live Longer Without Their Disease Returning Compared To Herceptin® And Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced positive results...

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's sovereign wealth fund, the world's biggest and a key investor in Apple and Alphabet, earned more than $53 billion last year as equity returns surged.

Argos Plummets 72%, Leads Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Also falling was Global Blood Therapeutics.

Phase II Study Supports Potential For Genentech's Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma

Phase II Study Supports Potential For Genentech's Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II IMmotion150 study that compared TECENTRIQ ® (atezolizumab) plus Avastin ® (bevacizumab)...

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Roche CEO Bullish on U.S. Drug Market

Roche CEO Bullish on U.S. Drug Market

Roche shares gain after the company's CEO says he's 'fully dedicated' to the key U.S. market.

Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market

Roche Shares Gain; CEO 'Fully Dedicated' to Key U.S. Market

Roche shares traded higher in Zurich on Wednesday after the company's CEO said he was bullish on its U.S. market.

Roche Posts Solid 2016 Profit, 2017 Outlook; Dividend Falls Short

Roche Posts Solid 2016 Profit, 2017 Outlook; Dividend Falls Short

Roche posted solid second-half earnings on Wednesday and said it expects single-digit sales growth in 2017, guidance that was largely in line with analysts' forecasts.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

FDA Grants Priority Review For Genentech's Actemra® (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, A Form Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?

Is It Time to Buy Beaten-Down Bristol-Myers Squibb Stock?

Bristol-Myers Squibb stock has fallen by 35% in the last six months.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

Breakthrough Development For Americans With Suspected Heart Attack - Next Generation Troponin T Test From Roche Cleared By FDA

New Troponin T 9-minute test offers greater sensitivity in the diagnosis of myocardial infarction

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.